Nephrectomy News and Research

RSS

Cytoreductive nephrectomy can extend survival of metastatic kidney cancer patients

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in ten such patients undergo the procedure, according to a new study by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital.

21 Jun 2016

Robotic nephrectomy for inferior vena cava tumor thrombus shows promise in selected patients

Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain. Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes in selected patients compared with open surgery, which can have a high rate of complications, report surgeons in The Journal of Urology.

8 Feb 2016

Upstate Medical University physicians use minimally invasive robotic surgery in complex IVC thrombus case

Physicians at Upstate Medical University in Syracuse describe in the December issue of Urology the first case ever in which doctors used minimally invasive robotic surgery to perform a radical nephrectomy (removal of entire kidney) with a level III inferior vena cava thrombectomy (removal of a tumor from the largest vein that carries blood to the heart).

27 Jan 2016

HealthWell Foundation opens new fund to provide financial assistance to Medicare patients suffering from RCC

The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, today announced it has opened a new fund to provide financial assistance to Medicare patients suffering from renal cell carcinoma (RCC).

31 Dec 2015

Argos Therapeutics begins AGS-003 clinical trial in patients with metastatic renal cell carcinoma

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the Arcelis technology platform, today announced the initiation of a single-center pilot clinical trial of AGS-003 as a neoadjuvant immunotherapy in patients with localized renal cell carcinoma.

11 Aug 2015

Doxorubicin omission feasible for select Wilms’ tumour patients

Stratifying patients by histological response to preoperative chemotherapy may allow some children with Wilms’ tumour to avoid doxorubicin and its associated cardiotoxicity, suggest study findings published in The Lancet.

15 Jul 2015

21st century trends in management of small renal cancers

A US population-based cohort study reveals a change in the management of small renal masses in the 21st century with rates of nephron-sparing surgery on the rise and a corresponding decrease in the use of radical nephrectomy.

29 May 2015

Quitting smoking can help improve outcomes after major urologic surgery

Quitting smoking can lead to a significant improvement in outcomes after major urologic surgery. These new data and their impact on urologic surgery will be highlighted by study authors during a special press conference at the 110th Annual Scientific Meeting of the American Urological Association.

17 May 2015

Limited anticancer role for preoperative statins in localised RCC setting

Statin use prior to undergoing nephrectomy is not associated with survival outcomes in patients with localised renal cell carcinoma, research suggests.

25 Mar 2015

Henry Ford physicians suction cancerous tumor from vein in metastatic kidney cancer patient

Physicians at Henry Ford Hospital successfully suctioned a cancerous tumor from a major vein in a patient with metastatic kidney cancer, clearing the way for him to undergo a minimally-invasive kidney removal. This allowed him to participate in a clinical trial using genetic material from his tumor to produce a vaccine to help fight his metastatic disease.

16 Feb 2015

Henry Ford physicians use AngioVac device to remove tumor in kidney cancer patient

13 Feb 2015

Close, active monitoring of small renal tumors linked to low rates of death

In patients likely to have surgery, close, active monitoring of small renal tumors confined to the kidneys is associated with low rates of tumor growth or death, according to a study by a researcher at the Icahn School of Medicine at Mount Sinai published in the September issue of The Journal of Urology.

22 Jan 2015

CDK activity predicts RCC recurrence

The specific activity of cyclin-dependent kinase 1 and CDK2 as well as a risk score based on the activity of these enzymes can predict recurrence in patients with renal cell carcinoma, study findings indicate.

19 Dec 2014

Study: Patients with operable kidney cancers more likely to have partial nephrectomy

Patients with operable kidney cancers were more likely to have a partial nephrectomy -- the recommended treatment for localized tumors -- when treated in hospitals that were early adopters of robotic surgery, according to a new study.

14 Dec 2014

Study suggests that hospitals perform more partial nephrectomies after acquiring robots

Hospitals with robotic surgical systems are more likely to perform "nephron-sparing" partial nephrectomy--a recommended alternative to removal of the entire kidney--in patients with kidney cancer, reports a study in the December issue of Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

12 Dec 2014

Statin use linked to improved RCC surgery outcomes

Statin use at the time of surgery is associated with improved overall survival and disease-specific survival in patients with renal cell carcinoma of any stage, US researchers report.

18 Nov 2014

Sarcomatoid differentiation levels predict poor RCC survival

Research shows that the degree of sarcomatoid differentiation in patients with grade 4 renal cell carcinoma is not only associated with poor survival, but can also serve as an independent prognostic factor in these patients.

14 Nov 2014

Toxicity profiles for everolimus, temsirolimus differ in advanced RCC

Non-infectious pneumonitis and stomatitis occur more frequently in patients with advanced renal cell carcinoma treated with everolimus than temsirolimus, whereas temsirolimus is associated with a higher incidence of fatigue, rash and asthenia, a retrospective study reports.

13 Nov 2014

Cytoreductive nephrectomy benefits limited by preoperative risk factors

The survival benefit of cytoreductive nephrectomy when used in conjunction with targeted therapy for metastatic renal cell carcinoma depends on the number of preoperative risk factors a patient carries, study findings indicate.